Trial Profile
Phase I clinical trial of CX1739 in normal volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs CX 1739 (Primary)
- Indications Respiratory insufficiency; Sleep apnoea syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors RespireRx Pharmaceuticals
- 06 Dec 2021 Status changed from recruiting to completed as per RespireRx Pharmaceuticals Inc media release.
- 15 Aug 2008 New trial record.